

I. AMENDMENTS

Please cancel claims 1 to 17, and 25 to 47 without prejudice.

Please amend claim 24 to read as follows:

24. (Amended) A method according to claim 18, wherein the first set of cells comprises
a different detectable label than the second set of cells.

Please add the following new claims:

--51. The method of claim 18, wherein the antibodies are multispecific antibodies.

52. The method of claim 51, wherein the multispecific antibodies are bispecific
antibodies.

53. The method of claim 18, wherein the antibodies are antigen-binding antibody
fragments.

54. The method of claim 53, wherein the antigen-binding antibody fragments are Fv,
Fab, Fab' or F(ab')₂ fragments.

55. The method of claim 18, wherein the antibodies are IgG, IgM, IgE or IgA antibodies.

56. The method of claim 18, wherein the antibodies are chimeric antibodies.

57. The method of claim 18, wherein the antibodies are humanized antibodies.

58. The method of claim 18, wherein the antibodies are single chain antibodies.

sub
C12
A2
cont'd

59. The method of claim 18, wherein the antibodies are diabodies.

60. The method of claim 18, wherein the solid surface comprises a plastic, a complex carbohydrate, an acrylic resin, nitrocellulose, or positively charged nylon.

61. The method of claim 18, wherein the solid surface comprises a glass slide, a silicon wafer, or a latex bead.

10035368 102601

(62) The method of claim 61, wherein the glass slides comprises aldehyde treated glass slides or nitrocellulose slides.

(63) The method of claim 18, wherein the solid surface comprises polycarbonate, agarose, or polyacrylamide.

~~64.~~ The method of claim 18, wherein at least one spot in the array of antibodies contains about 0.01 ng to 100 ng of antibody.

~~65.~~ The method of claim 18, wherein the antibodies have an affinity greater than about 10^{-6} M.

~~66.~~ The method of claim 65, wherein the antibodies have an affinity greater than about 10^{-7} M.

~~67.~~ The method of claim 65, wherein the antibodies have an affinity of about 10^{-8} M to 10^{-11} M.

In re Application of
Hoeffler et al.
Filed: Herewith
Divisional Appl. of
U.S. Serial No. 09/245,615
Page 4

PATENT
Attorney Docket No.: INVIT1100-2

A2 sub
cont'd
68. The method of claim 18, wherein the first cell lysate comprises an arterial endothelial cell lysate and the second cell lysate comprises a venous endothelial cell lysate.

69. The method of claim 18, wherein the first cell lysate or the second cell lysate or both comprises a bacteria lysate, a parasite lysate or a virus lysate.

70. The method of claim 23, wherein the normal cells are T cells.--

10035368-102601